A new calcium channel antagonist, lomerizine, alleviates secondary retinal ganglion cell death after optic nerve injury in the rat

Current Eye Research

Volumn 31, Issue 3, 2006, Pages 273-283

  Karim, Md Zahidul ^a   Sawada, Akira ^a   Kawakami, Hideaki ^a   Yamamoto, Tetsuya ^a   Taniguchi, Takazumi ^b  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SANTEN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Calcium channel blocker; Lomerizine; Neuroprotection; Optic nerve injury; Retinal ganglion cell

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; FLUOROGOLD; LOMERIZINE; PIPERAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AXONAL INJURY; AXOPLASM; CELL DENSITY; CELL LABELING; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; HISTOLOGY; INFERIOR COLLICULUS; MALE; NERVE CRUSH; NEUROPROTECTION; NONHUMAN; OPTIC NERVE INJURY; PRIORITY JOURNAL; RAT; RETINA GANGLION CELL; RETINA INJURY; TREATMENT OUTCOME;

ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL COUNT; CELL DEATH; CELL SURVIVAL; MALE; OPTIC NERVE INJURIES; PIPERAZINES; RATS; RATS, WISTAR; RETINAL GANGLION CELLS; TREATMENT OUTCOME;

EID: 33644892233     PISSN: 02713683     EISSN: None     Source Type: Journal    
DOI: 10.1080/02713680500536647     Document Type: Article

References (52)

1. Adachi K, Kashii S, Masai H, et al. Mechanism of pathogenesis of glutamate neurotoxicity in retinal ischemia. Graefes Arch Clin Exp Ophthalmol. 1998;23:766-774.
2. Buchi ER. Cell death in the rat retina after a pressure-induced ischemia reperfusion insult. An electron microscopic study: ganglion cell layer and inner nuclear layer. Exp Eye Res. 1992;55:605-613.
3. Weber M, Bonaventure N, Sahel JA. Protective role of excitatory amino acid antagonists in experimental retinal ischemia. Grafes Arch Exp Ophthalmol. 1995;233:360-365.
4. Wu SM, Maple BR. Amino acid neurotransmitters in the retina: a functional overview. Vis Res. 1998;38:1371-1384.
5. Bloomfield SA, Dowling JE. Roles of aspartate and glutamate in synaptic transmission in rabbit retina. I. Outer plexiform layer. J Neurophysiol. 1985;53:699-713.
6. Bloomfield SA, Dowling JE. Roles of aspartate and glutamate in synaptic transmission in rabbit retina. II. Inner plexiform layer. J Neurophysiol. 1985;53:714-725.
7. Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999;43:S102-128.
8. Melena J, Osborne NN. Voltage-dependent calcium channels in the rat retina: involvement in NMDA-stimulated influx of calcium. Exp Eye Res. 2001;72:393-401.
9. Cohn JN. Calcium, vascular smooth muscle, and calcium entry blockers in hypertension. Ann Intern Med. 1983;98:806-809.
10. Hof RP. Calcium antagonist and the peripheral circulation: differences and similarities between PY 108-068, nicardipine, verapamil, and diltiazem. Br J Pharmacol. 1982;78:375-394.
11. Yamamoto T, Kitazawa Y. Vascular pathogenesis of normal-tension glaucoma: a possible pathogenetic factor, other than intraocular pressure, of glaucomatous optic neuropathy. Prog Retin Eye Res. 1998;17:127-143.
12. 2+ channel blocker, on the normal and endothelin-1-disturbed circulation in the optic nerve head of rabbits. J Ocul Pharmacol Ther. 2001;17:131-149.
13. 3H]nitrendipine binding. Jpn J Pharmacol. 1988;48:241-247.
14. 2+ entry blocker, of the contractile response of isolated cerebral arteries in the dog. Folia Pharmacol Jpn. 1987;89:365-373.
15. Kanazawa T, Nakasu Y, Matsuda M, Handa J. Acute effects of 1 -[bis-(4-fluorophenyl)methyl]-4-(2,3,4-trimethoxybenzyl)-piperazine dihydrochloride, KB-2796, on cerebral blood flow in unanesthetized cats. Arch Jpn Chir. 1986;55:682-688.
16. Yamada C, Harada K, Shimamoto A, et al. Effects of lomerizine on cerebral blood flow and systemic arterial blood pressure in anesthetized dogs. Jpn Pharmacol Ther. 1997;25:797-802.
17. 2+ current and oxidative metabolism in dissociated mammalian CNS neurons. Brain Res. 1993;619:263-270.
18. 2+ antagonist, on glutamate-induced neurotoxicity in rat hippocampal primary cell cultures. Jpn J Pharmacol. 1993;61:361-365.
19. Hara H, Ozaki A, Yoshidomi M, Sukamoto T. Protective effect of KB-2796, a new calcium antagonist, in cerebral hypoxia and ischemia. Arch Int Pharmacodyn Ther. 1990;304:206-218.
20. Levkovitch-Verbin H, Quigley HA, Martin KR, et al. A model to study differences between primary and secondary degeneration of retinal ganglion cells in rats by partial optic nerve transection. Invest Ophthalmol Vis Sci. 2003;44(8):3388-3393.
21. Honjo M, Tanihara H, Kido N, et al. Expression of ciliary neurotrophic factor activated by retinal Muller cells in eyes with NMDA-and kainic acid-induced neuronal death. Invest Ophthalmol Vis Sci. 2000;41:552-560.
22. Perry VH. Evidence for an amacrine cell system in the ganglion cell layer of the rat retina. Neuroscience. 1981;6:931-944.
23. Dreyer EB, Zurakowski D, Schumer RA, et al. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol. 1996;114:299-305.
24. Sucher NJ, Lei SZ, Lipton SA. Calcium channel antagonists attenuate NMDA receptor-mediated neurotoxicity of retinal ganglion cells in culture. Brain Res. 1991;551:297-302.
25. Weiss JH, Hartley DM, Koh J, Choi DW. The calcium channel blocker nifedipine attenuates slow excitatory amino acid neurotoxicity. Science 1990;247:1474-1477.
26. 2+ channel blocker, reduces glutamate-induced neurotoxicity and ischemia/reperfusion damage in rat retina. Exp Eye Res. 2000;70:475-484.
27. Schwartz M. Optic nerve crush: protection and regeneration. Brain Res Bull. 2004;62:467-471.
28. Yoles E, Muller S, Schwartz M. NMDA-receptor antagonist protects neurons from secondary degeneration after partial optic nerve crush. J Neurotrauma. 1997;14:665-675.
29. Klocker N, Zerfowski M, Gellrich NC, Bahr M. Morphological and functional analysis of an incomplete CNS fiber tract lesion: graded crush of the rat optic nerve. J Neurosci Methods. 2001;110:147-153.
30. Sawada A, Neufeld AH. Confirmation of the rat model of chronic, moderately elevated intraocular pressure. Exp Eye Res. 1999;69:525-531.
31. Selles-Navarro I, Villegas-Perez MP, Salvador-Silva M, et al. Retinal ganglion cell death after different transient periods of pressure-induced ischemia and survival intervals: a quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996;37:2002-2014.
32. Barres BA, Jacobson MD, Schmid R, et al. Does oligodendrocyte survival depend on axons? Curr Biol. 1993;3(8):489-497.
33. Crowe MJ, Bresnahan JC, Shuman SL, et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med. 1997;3(1):73-76.
34. Levkovitch-Verbin H, Quigley HA, Kerrigan-Baumrind LA, et al. Optic nerve transection in monkeys may result in secondary degeneration of retinal ganglion cells. Invest Ophthalmol Vis Sci. 2001;42(5):975-982.
35. Berkelaar M, Clarke DB, Wang YC, et al. Axotomy results in delayed death and apoptosis of retinal ganglion cells in adult rats. J Neurosci. 1994;14(7):4368-4374.
36. Maxwell WL, Watt C, Graham DI, Gennarelli TA. Ultrastructural evidence of axonal shearing as a result of lateral acceleration of the head in non-human primates. Acta Neuropathol. 1993;86:136-144.
37. Maeda K, Sawada A, Matsubara M, et al. A novel neuroprotectant against retinal ganglion cell damage in a glaucoma model and an optic nerve crush model in the rat. Invest Ophthalmol Vis Sci. 2004;45:851-856.
38. Moalem G, Monsonego A, Shani Y, et al. Differential T cell response in central and peripheral nerve injury: connection with immune privilege. FASEB J. 1999;13:1207-1217.
39. McKerracher L, Hirscheimer A. Slow transport of the cytoskeleton after axonal injury. J Neurobiol. 1992;23:568-578.
40. Lafuente Lopez-Herrera MP, Mayor-Torroglosa S, Miralles de Imperial J, et al. Transient ischemia of the retina results in altered retrograde axoplasmic transport: neuroprotection with brimonidine. Exp Neurol. 2002;178:243-258.
41. Zhang L, Inoue M, Dong K, Yamamoto M. Retrograde axonal transport impairment of large-and medium-sized retinal ganglion cells in diabetic rat. Curr Eye Res. 2000;20:131-136.
42. Minckler DS, Bunt AH, Johanson GW. Orthograde and retrograde axoplasmic transport during acute ocular hypertension in the monkey. Invest Ophthalmol Vis Sci. 1977;16:426-441.
43. Quigley HA, Addicks EM, Green WR, Maumenee AE. Optic nerve damage in human glaucoma. II. The site of injury and susceptibility to damage. Arch Ophthalmol. 1981;99:635-649.
44. Chan SY, Ochs S, Worth RM. The requirement for calcium ions and the effect of other ions on axoplasmic transport in mammalian nerve. J Physiol. 1980;301:477-504.
45. Johansson JO. Influence of low IOP and low calcium on retrograde axoplasmic transport in rat optic nerve in vitro. Exp Eye Res. 1985;41:739-744.
46. Taft WC, Clifton GL, Blair RE, DeLorenzo RJ. Phenytoin protects against ischemia-produced neuronal cell death. Brain Res. 1989;483:143-148.
47. +: evidence that microtubules are not required. Proc Natl Acad Sci USA. 1980;77:5909-5913.
48. Lees GJ. Inhibition of the retrograde axonal transport of dopamine-beta-hydroxylase antibodies by the calcium ionophore A23187. Brain Res. 1985;345:62-67.
49. Osborne NN, Cazevielle C, Carvalho AL, et al. In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent. Brain Res. 1997;751:113-123.
50. Osborne NN, DeSantis L, Bae JB, et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res. 1999;69:331-342.
51. Takahashi K, Lam TT, Edward DP, et al. Protective effects of flunarizine on ischemic injury in the rat retina. Arch Ophthalmol. 1992;110:862-870.
52. Eschweiler GW, Bahr M. Flunarizine enhances rat retinal ganglion cell survival after axotomy. J Neurosci Sci. 1993;116:34-40.